-

Shareholder Alert: Robbins LLP Announces Norwegian Cruise Line Holdings Ltd. (NCLH) Sued for Misleading Shareholders

SAN DIEGO & MIAMI--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 20, 2020 and March 12, 2020. Norwegian operates as a cruise company internationally.

If you suffered a loss as a result of Norwegian's misconduct, click here.

Norwegian Cruise Line Holdings Ltd. (NCLH) Accused of Misleading Shareholders

According to the complaint, on February 20, 2020, Norwegian touted that "despite the current known impact from the COVID-19 coronavirus outbreak…the Company's booked position remained ahead of prior year and at higher prices" and assured its confidence in a strong financial performance for the Company long-term. Later that month, Norwegian stated in its 2019 annual report that the Company "place[s] the utmost importance on the safety of [its] guests and crew" and it was "proactively protecting the health of travelers." Then, on March 11, 2020, the Miami New Times reported on leaked emails from Norwegian's staff that revealed Norwegian had directed its sales staff to lie to customers regarding COVID-19 "to protect the company's bookings." On March 12, 2020, The Washington Post detailed some of the lies, which included statements like "the coronavirus will not affect you" and "fact: coronavirus in humans is an overhyped pandemic scare." On this news, shares of Norwegian fell almost 53% to close at $9.65.

If you purchased Norwegian Cruise Line Holdings Ltd. (NCLH) securities between February 20, 2020 and March 12, 2020, you have until May 11, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:NCLH

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom